Roche’s Tecentriq/Abraxane Combo for TNBC Approved by EU

The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer

Roche announced that the European Commission has approved Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [nab-paclitaxel]) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression (≥1%) and who have not received prior chemotherapy for metastatic disease. Roche’s VENTANA PD-L1 (SP142) Assay is now CE marked and commercially available in the European Union as an aid for identifying patients ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters